Guidance for Safety and Dosing of Medicines in Patients With Cirrhosis Is Available
Main Authors: | Rianne A. Weersink, Joost P.H. Drenth, Nicole G.M. Hunfeld, Sander D. Borgsteede |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2019-09-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1399 |
Similar Items
-
Why zolpidem increases the risk of falls and fractures in patients with cirrhosis
by: Rianne Antoinet Weersink, et al.
Published: (2022-12-01) -
Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver Disease
by: Rianne A. Weersink, et al.
Published: (2021-04-01) -
Improving Medication‐Related Outcomes in Chronic Liver Disease
by: Kelly L. Hayward, et al.
Published: (2020-11-01) -
Aldosterone Antagonist Dosing and the Risk of Hyponatremia in Patients With Cirrhosis and Ascites
by: A.S. Vogel, et al.
Published: (2023-01-01) -
Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data
by: Kelly L. Hayward, et al.
Published: (2023-10-01)